Vision Expo East 2024: Shedding light on orthokeratology with Dr Brianna Rhue
March 14th 2024Dr Brianna Rhue, OD, FAAO, FSLS details her upcoming presentation "Cutting Out Surgery for the Management of Refractive Error," where she will detail the underutilization of orthokeratology during Vision Expo East 2024 later this week.
Diagnose, treat, and prevent: What's to come at the 2024 IKA Keratoconus Symposium
March 1st 2024Barry Eiden, OD, FAAO, FSLS, sits down with Optometry Times to highlight the importance of staying up-to-date with technology in the development of treatment and diagnosis of keratoconus and what's to come at this year's IKA Keratoconus Symposium in May.
Innovent Biologics meets primary endpoint for Phase 3 clinical trial, plans to submit NDA
February 28th 2024A treatment option for thyroid eye disease may be on its way to finalization in China with the positive endpoint results from a Phase 3 clinical trial of IBI311, a recombinant anti-insulin-like growth factor 1 receptor antibody.
Keep your eye on the ball: Chicago Bulls, White Sox team eye doctor weighs in on treating athletes
February 28th 2024R Tracy Williams, OD, FAAO, has been team optometrist for the Chicago Bulls and White Sox for over 20 years. He details how treatment of professional athletes is different than the general public in an exclusive interview with Optometry Times.
Alcon announces MARLO updates with anticipated unveiling of new app at SECO 2024
February 27th 2024The eye care device company has announced that MARLO has gone mobile with a new app, which allows patients to order contact lenses, perform vision screening, and access eye disease and care information.
IKA Keratoconus Symposium to bring "best of the best"
February 22nd 2024Andrew S. Morgenstern, OD, FAAO, FNAP sits down with Optometry Times to reiterate under-utilized diagnostic tools for keratoconus and the planning of this year's International Keratoconus Academy Keratoconus Symposium, running from May 18-19 in Bethesda, Maryland.
Opthea Limited completes enrollment for 1 of 2 Phase 3 sozinibercept (OPT-302) trials
February 19th 2024The clinical-stage biopharmaceutical company is running 2 Phase 3 clinical trials, COAST and ShORe, to assess the efficacy and safety of using combinations of certain drugs to treat wet age-related macular degeneration.